We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cincinnati Children's Hospital Medical Center has signed a licensing deal that
gives Girindus AG access to the hospital's portfolio of more than 30 skin-lightening
patents.
Merck & Co., the second-biggest U.S. drugmaker, has started shutting off
sales to Canadian pharmacies exporting drugs to American patients, adding to
manufacturers' efforts to disrupt the cross-border trade.
Sigma-Aldrich has signed a definitive agreement to acquire the JRH Biosciences
division (JRH) of CSL, for $370 million in cash, subject to normal closing adjustments.
Pfizer is in talks to acquire a private biotechnology company called Angiosyn,
which is developing a drug for macular degeneration, the leading cause of blindness
in the elderly.
Sweden's Meda AB has signed an agreement with the
Swiss pharmaceutical company Novartis AG regarding the acquisition of the pharmaceuticals
Cibacen and Cibadrex.
Chiron President and CEO Howard Pien has confirmed that the fate of the company's
Liverpool, England, manufacturing facility will hinge on a series of upcoming
inspections to be performed by the UK's Medicines and Healthcare products Regulatory
Agency (MHRA).
The FDA's funding program for clinical trials investigating orphan drugs will
undergo some changes in fiscal 2006, including alterations to the way funding
limitations are established, according to a notice released by the agency.
An evidence-based approach to medicine -- in which treatments
are compared and selected based on effectiveness and value -- can lower costs
and improve healthcare services, according to HHS officials.
Eli Lilly has launched an initiative to correct what it says are inaccurate
statements made about the company and its antidepressant Prozac in a prominent
British medical journal and other media.